APAS Data Explorer
  • View maps
  • About the data
  • Links
    • APAS
Disclaimer The content contained in this Data Explorer is published in good faith by the Australian Commission on Safety and Quality in Health Care for information purposes only. The content is not intended to provide guidance on particular healthcare choices. Users should exercise their own skill and care when using this content and carefully evaluate its accuracy, currency, completeness and relevance for their purposes. You should contact your healthcare provider on particular healthcare choices. The Australian Commission on Safety and Quality in Health Care and the Australian Centre for Disease Control do not accept any legal liability for any injury, loss or damage incurred by the use of, or reliance on, this information.

Data extracted on 22 July 2026

Notes:

  • n = total number of isolates
  • %R = percentage of resistant isolates

About AURA

The Commission's Antimicrobial Use and Resistance in Australia (AURA) Project contributes to the AURA surveillance program, which is coordinated and funded by the the Australian Centre for Disease Control (CDC), with voluntary contributions from the states, territories and private pathology services as part of the collection and analysis of their data. AURA data on antimicrobial resistance (AMR) inform strategies for infection prevention and control and antimicrobial stewardship.

About APAS

Australian Passive AMR Surveillance (APAS) is coordinated by the Commission in collaboration with Queensland Health and is a key component of the AURA surveillance program. APAS collects, analyses and reports on AMR data from routine susceptibility testing results from participating public and private pathology services across Australia. APAS contains de-identified patient-level AMR data collected from hospitals, aged care, and community settings across Australia.

The Commission acknowledges and thanks all pathology services that contribute to APAS.

About the data

  • Data represent clinical infections; Data are from isolates reported from all specimens collected for diagnostic purposes unless stated.
  • Data from isolates detected in infection control and environmental sampling are excluded.
  • Data are only included where there are at least 30 isolates for each analysis.
  • For resistance in E. faecium, E. coli, K. pneumoniae and S. aureus: Analyses are conducted only when the proportion of isolates that were tested against a single antimicrobial or related pair of antimicrobials was at least 75%.
  • For resistance in S. pneumoniae: Analyses are conducted only when the proportion of isolates that were tested against a single antimicrobial or related pair of antimicrobials was at least 70%.
  • Only the first isolate for the first specimen of each specimen type per year is included in the dataset for analyses.
  • APAS data report on antimicrobials tested by the participating pathology service using the European Committee on Antimicrobial Susceptibility Testing (EUCAST), the Clinical and Laboratory Standards Institute (CLSI) or the Calibrated Dichotomous Sensitivity (CDS) method.
  • APAS provides categorical data (susceptible, intermediate [susceptible increased exposure], resistant) based on interpretive criteria as determined by the participating pathology service.
  • Data are mapped to Australian Statistical Area Level 4 (SA4) based on postcode of residence (where known); Data are also mapped to Australian Statistical Area Level 3 (SA3) if there is a sufficient number of isolates available. SA4s are the largest sub-state regions, which are geographic areas built from whole SA3s.
  • Data are not available from Northern Territory, except where a resident received pathology services in another jurisdiction.
  • Data are not available from Mater Pathology Queensland from December 2024.

For more information about APAS, methodology and considerations for analyses, see the Appendices of Australian Passive AMR Surveillance: Resistance trends in Streptococcus pneumoniae – 2006 to 2025.